Tiburio Therapeutics, Inc.

Tiburio is Cydan’s third orphan drug company, launched in January of 2019 with $31M in financing. Tiburio is a clinical stage biopharmaceutical company dedicated to…

Imara Inc. is Cydan’s second orphan drug company, launched with $31M in financing in April 2016. Imara is developing IMR-687, a disease-modifying therapy for the…

Vtesse, Inc. was Cydan’s first spin co and was dedicated to developing drugs for patients suffering from diseases that are underserved. Vtesse worked collaboratively with…